Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Wound Care
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 368489
Licensee is a biopharmaceutical company developing synthetic peptide compounds targeted at tissue repair and regeneration.
IPSCIO Record ID: 28032
TP508 is a 23-amino acid synthetic peptide representing a receptor-binding domain of the human thrombin molecule, a naturally occurring molecule in the body responsible for both blood clotting and initiating many of the cellular events responsible for tissue repair in bone and cartilage. A single topical application of TP508 stimulates revascularization and healing of acute incisional and excisional wounds in normal, healthy rat skin.
IPSCIO Record ID: 160766
Licensor Technology means the core technologies related to the Patents, including the TP508 Peptide.
Licensor Product means TP508 or any related peptides, or any other materials or products manufactured by or for Licensor and sold to Licensee for research, treatment of patients or resale.
Patents means U.S. patents Number 5,352,664 and 5,500,412, all related foreign patents, including patents issued in Europe, Canada and Japan, and any divisional, continuation, and continuation-in-part applications and patents based thereon, any reissues or extensions thereof, and any corresponding or additional United States and foreign patent applications.
IPSCIO Record ID: 3187
Subsequently, Licensee entered into an Agreement whereby the University of Texas assigned to the Licensee certain patents previously exclusively Licensed to the Licensee.
Chrysalin has been patented in the United States and in some other countries for a number of methods of use, including cardiovascular indications.
A composition of matter patent covering European countries expired in 2007 and the corresponding United States patent expired in 2011. Our other patents for Chrysalin expire between 2021 and 2024.
On January 20, 2012, the Licensee announced the intent to cease all activities related to the development of Chrysalin and to return the patent and other intellectual property we own related to Chrysalin to the original licensor.